Clearmind Medicine announced the US publication of three patent applications covering LSD, ketamine and ibogaine combinations with N-acylethanolamines for potential therapeutic uses.

The applications cover combinations involving palmitoylethanolamide, or PEA, for potential use in depression, PTSD, pain and substance use disorders, including alcohol use disorder. The filings expand Clearmind’s intellectual property collaboration with NeuroThera Labs, following a previously announced application covering MDMA with N-acylethanolamines.